ClinicalTrials.gg
RecruitingNCT06796803Updated Jul 17, 2026

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

A Phase 2/3 interventional study of camrelizumab combined with rivoceranib and HAIC and camerlizumab + rivoceranib in Potentially Resectable Hepatocellular Carcinoma, sponsored by Shanghai Zhongshan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Shanghai Zhongshan Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing camrelizumab in Carcinoma, Hepatocellular — 19 open to participants now, 24 under way, 8 of them phase 3. camrelizumab · Carcinoma, Hepatocellular.

Planned enrollment
3rd of 44
398 · median 51
Started
2025
with 1 other
Phase 2/3
3 of 44
2 open now
Primary completion
2028-02
later than 23 of 23 live
Registered
41st of 44
by date
Lead sponsor
5 of 44
Shanghai Zhongshan Hospital

Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 23 of the 23 other live ones, and was the 41st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

19 of the 44 studies testing camrelizumab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing camrelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Read the detailed description

This is a multicenter, open-label, randomized study designed to evaluate the efficacy and safety of camrelizumab combined with rivoceranib and HAIC as conversion therapy.

Eligible patients will be randomized into camrelizumab + rivoceranib + HAIC group and camrelizumab + rivoceranib group. Patients in camrelizumab + rivoceranib + HAIC group will receive systemic therapy and no more than 6 cycles HAIC procedure. Tumor response assessment using CT and/or MRI will be conducted according to RECIST v1.1. Those who are assessed as CR/PR or SD and considered suitable for curative hepatic resection will receive surgry. Surgical approaches will be tailored to the individual patient according to local standards with the goal of achieving R0 resection.The first administration of postoperative camrelizumab + rivoceranib treatment is recommended to start within 4-6 weeks after surgery, requiring full recovery from the surgery prior to post-operative camrelizumab + rivoceranib treatment. Patients in camrelizumab + rivoceranib group will receive the systemic therapy until progression or unacceptable toxicity.

03

Conditions studied

  • Potentially Resectable Hepatocellular Carcinoma

Keywords

  • conversion therapy
  • hepatocellular carcinoma
  • camrelizumab and rivoceranib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form (ICF)
  2. Aged ≥18 years and ≤75 years at time of signing ICF
  3. Documented diagnosis of HCC confirmed by histology/cytology or clinically
  4. Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic : ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium
  5. Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry
  6. At least one (per v1.1) untreated lesion
  7. performance status of 0 or 1
  8. ≤7 score
  9. ≥12 weeks
  10. Adequate organ function
  11. No prior anti-tumor systemic therapies for HCC

Exclusion criteria

Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  2. Other active malignant tumor except HCC within 5 years or simultaneously
  3. Prior locoregional therapy (such as TACE、TAE、HAIC、TARE)
  4. There is an absolute to HAIC
  5. History of hepatic encephalopathy
  6. Diffuse HCC, intrahepatic tumor burden > 50%
  7. PVTT reaching the superior mesenteric vein, and bilateral PVTT are present
  8. ascites
  9. Prior allogeneic stem cell or solid organ transplantation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    camrelizumab + rivoceranib + HAIC

    Drug: camrelizumab combined with rivoceranib and HAIC

  • Active comparator
    camrelizumab + rivoceranib

    Drug: camerlizumab + rivoceranib

Interventions

06

What researchers measure

Primary outcomes

  1. R0 rate

    R0 rate defined as the proportion of patients who accomplish the complete resection of tumor with pathologically confirmed negative margin

    Time frame: 24 months

  2. dual primary endpoint: EFS and OS

    Event-free survival (EFS), defined as the time from randomization to progression (RECIST v1.1), recurrence and death from any cause. Overall survival (OS) after randomization, defined as the time from randomization to death from any cause

    Time frame: 36 months

Secondary outcomes

  1. ORR

    Objective response rate (ORR), defined as the percentage of subjects with complete response (CR) or partial response (PR) evaluated based on RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Overall Response (OR)=CR+PR.

    Time frame: 24 months

  2. DCR

    Disease Control Rate (DCR), defined as the percentage of subjects with complete response, partial response or stable disease (SD) ≥ 8 weeks evaluated based on RECIST v1.1. Complete response (CR) was defined as Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameter of TL, taking as reference the baseline sum of diameters. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: 24 months

  3. pCR rate

    Pathological complete regression (pCR) rate, defined as the proportion of patients with no evidence of vital residual tumor cells on the complete resected specimen. pCR status will be analyzed by local pathologists at each site

    Time frame: 24 months

  4. MPR rate

    MPR rate, defined as the proportion of patients with evidence of vital residual tumor cells on the resected specimen. MPR status will be analyzed by local pathologists at each site

    Time frame: 24 months

  5. AE

    Adverse events are graded according to the NCI-CTCAE (Version 5.0)

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 28, 2025
StartActual
Feb 20, 2025
Primary completionEst.
Feb 20, 2028
CompletionEst.
Feb 28, 2030
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06796803
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Feb 20, 2025
Primary completion
Feb 20, 2028 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Jul 17, 2026

Study contacts

Huichuan Sun, MD, PHD
Contact
sun.huichuan@zs-hospital.sh.cn
sun.huichuan@zs-hospital.sh.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion